Dr Reddy’s to exclusively distribute Takeda’s Qdenga dengue vaccine in India from H1 2027
Dr Reddy’s Laboratories will promote and distribute Takeda’s two-dose Qdenga dengue vaccine in India’s private market from the first half of 2027. The CDSCO-approved vaccine is indicated for people aged 4 to 60 years and will be administered in two doses, three months apart.
What happened
Dr. Reddy’s Laboratories · Dr Reddy’s will exclusively promote and distribute Takeda’s Qdenga dengue vaccine in India’s private market from the first half of
Key facts
- Qdenga will be available in India in the first half of 2027
- CDSCO approved the vaccine in July 2026
- Approved for individuals aged 4-60 years
- Two-dose regimen administered three months apart
What changed
Dr Reddy’s will exclusively promote and distribute Takeda’s Qdenga dengue vaccine in India’s private market from the first half of 2027, following CDSCO approval. The two-dose vaccine is approved for people aged 4-60 and targets pediatric and adult vaccination.
Why this matters
Dr Reddy’s gains a meaningful private-market launch opportunity in dengue prevention, requiring strong physician education, cold-chain execution and two-dose patient adherence ahead of H1 2027.
What to watch
- Final launch timing, list price and channel margins for Qdenga in India.
- Takeda and Dr Reddy's disclosure of sales targets, initial city/state rollout and supply commitments.
- Physician guidance and Indian public-health recommendations on dengue vaccine use, including any changes to eligible populations.
- Evidence on two-dose completion rates, adverse-event monitoring and real-world effectiveness after launch.
- Competitor dengue-vaccine approvals, pricing actions or local manufacturing announcements.
Also reported by
- The Hindu BusinessLine — Same time